

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	NUNC PRO TUNC ASSIGNMENT
EFFECTIVE DATE:	02/01/1998

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Bio-Technology General Corporation (now known as Savient Pharmaceuticals, Inc.)		02/01/1998	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Bio-Technology General (Israel) Ltd.
Street Address:	Kiryat Weizmann
City:	Rehovot
State/Country:	ISRAEL
Postal Code:	76326
Entity Type:	CORPORATION: ISRAEL

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Serial Number:	74630640	BIOLON

CORRESPONDENCE DATA

Fax Number: (212)425-5288
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 212-425-7200
 Email: tmdocketny@kenyon.com
 Correspondent Name: Asiyah McCarthy
 Address Line 1: One Broadway
 Address Line 4: New York, NEW YORK 10004

DOMESTIC REPRESENTATIVE

Name: Howard J. Shire, Esq.
 Address Line 1: One Broadway

CH \$40.00 74630640

Address Line 4: New York, NEW YORK 10004

NAME OF SUBMITTER:

Howard J. Shire, Esq.

Signature:

/Howard J. Shire/

Date:

07/07/2005

Total Attachments: 3

source=biolon assignment#page1.tif

source=biolon assignment#page2.tif

source=biolon assignment#page3.tif

CONFIRMATORY ASSIGNMENT

This Assignment is by and between:

BIO-TECHNOLOGY GENERAL CORPORATION ("BTG"), currently known as Savient Pharmaceuticals, Inc., a corporation duly organized under the laws of Delaware, which as of February 1, 1998 had a place of business at 375 Park Avenue, New York, New York 10152, and which currently has a place of business at One Tower Center Boulevard, 14th Floor, East Brunswick, New Jersey 08816 (hereinafter referred to as "Assignor")

- and -

BIO-TECHNOLOGY GENERAL (ISRAEL) LTD. ("BTGIL"), a corporation duly organized and existing under the laws of Israel, and having a place of business at Kiryat Weizmann, 76326 Rehovot, Israel (hereinafter referred to as "Assignee").

WHEREAS as of February 1, 1998, Assignee and BTGIL entered into an agreement, whereby Assignee became the owner of all right, title and interest in and to the trademark and trademark application set forth in Schedule A (the "Mark") and the portion of BTG's business to which the Mark pertained; and

WHEREAS the parties are desirous of confirming and memorializing the transfer of all legal right, title and interest in and to the Mark together with any goodwill appurtenant thereto, the business associated therewith, and any and all past and present rights which have accrued to Assignor incident or appertaining to the Mark.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor, by these presents, does sell, assign and transfer *nunc pro tunc* as of February 1, 1998 unto the Assignee the entire right, title and interest in and to the Mark together with the goodwill appurtenant thereto and the portion of the business to which the Mark pertains, and any common law rights in and to the Mark, the same to be held and enjoyed by the Assignee as fully and entirely as the same would have held by Assignor had such assignment not been made, which assignment and transfer includes any and all past and present rights which have accrued or may accrue to Assignor, of any and all kind or nature incident or appertaining to the Mark, including the right to sue for and recover any accrued damages for infringement occurring prior to assignment of the Mark.

Signed this 22nd day of June 2005.

BIO-TECHNOLOGY GENERAL CORPORATION
(currently known as SAVIENT PHARMACEUTICALS, INC.)

Name: Philip H. Yachtmetz

Title: VP - Corporate Strategy
General Counsel

SCHEDULE A

TRADEMARK

SER. NO.

FILING DATE

BIOLON

74/630,640

February 6, 1995

MADE IN THE U.S.A.
2000